Biotech/Pharma Stock News; BioSante Pharmaceuticals (NASDAQ: BPAX) to Host LibiGel® R&D Event in New York City

LINCOLNSHIRE, Ill. - April 4, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) will host a review of female sexual dysfunction (FSD) and the safety of testosterone in women by independent experts, as well as an update of the LibiGel (testosterone gel) development program, for institutional investors and analysts on Thursday, April 7, 2011 in New York City. LibiGel is in Phase III clinical development for the treatment of FSD, specifically, hypoactive sexual desire disorder (HSDD) in menopausal women. Data from both LibiGel Phase III efficacy trials is expected in Fall 2011.

The LibiGel R&D Event will include presentations by independent experts in the fields of FSD and testosterone therapy, and BioSante�s management will speak about the LibiGel Phase III clinical development progress. The independent experts� presentations include:
"Hypoactive Sexual Desire in Postmenopausal Women," by Sheryl Kingsberg, PhD � Chief, Division of Behavioral Medicine, University Hospitals Case Medical Center, MacDonald Women's Hospital; Professor of Reproductive Biology and Psychiatry, Case Western Reserve University School of Medicine, Cleveland, Ohio.
"Update on Testosterone Safety in Women," by Glenn D. Braunstein, MD � Chairman, Department of Medicine, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California.
Interested parties may access the presentation slides and an audio recording after the event on BioSante�s website at www.biosantepharma.com.
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). Enrollment has been completed in the two on-going Phase III efficacy trials which are double-blind, placebo-controlled trials of approximately 500 surgically menopausal women each. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
BioSante also is conducting a Phase III LibiGel safety study, a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that has enrolled over 3,000 women. The study will continue for a total of five years, however, BioSante can use the safety study data as part of an NDA submission after an average of 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).

Invesorideas.com and SmallCapVoice.com Announce Online Investor Conference for Mining Stocks

April 4, 2011 - Investorideas.com and SmallCapVoice.com, two well known leaders in the small cap market, announce they have joined forces to co-produce this years biggest and best online investor conference for mining stocks. The online event scheduled for May 25th and May26th will feature leading industry experts speaking on the future of the mining sector, along with management of well- followed mining stocks.

The presentations will be an audio format with PowerPoint, averaging 10-15 minutes in length.
The event will be pre-recorded and go live May 25 th starting at 9:00 a.m. EST.
The information on the conference, presenters, registration and login will be featured on both www.investorideas.com and www.SmallCapvoice.com this week.
One of the well known speakers in the industry presenting is Peter Grandich.
Grandich is the founder of Grandich.com and Grandich Publications, LLC, and is editor of The Grandich Letter which was first published   in 1984. On his internationally-followed blog, he comments daily about the world’s economies and financial markets and posts his views on social and political topics.  He also blogs about a variety of timely subjects of general interest and interweaves his unique brand of humor and every-man “Grandichism” expressions with his experience gained from more than 25 years in and around Wall Street. The result is an insightful and intuitive look at business, finances and the world, set in a vernacular that just about anyone can understand. In his first year, Grandich’s wildly-popular blog had more than one million views. Grandich also provides a variety of services to publicly-held corporations on a compensation basis.
About our Mining Portals:
www.Gold-MiningStocks.com and www.MiningSectorStocks.com are research portals within the InvestorIdeas.com content umbrella, featuring industry and stock news, exclusive articles and financial columnists, audio interviews and podcasts, investor conferences, blogs, and a directory of over 1200 mining stocks.
About InvestorIdeas.com: Investor Ideas that Can Change the World
Investor Ideas is a global financial media online destination specialized in sector investing content including mining and energy stocks.
About SmallCapVoice.com, Inc.: Specializing in Covering Small Cap Stocks & Providing Small Cap Investor Relations
Recognized corporate investor relations firm SmallCapVoice.com, Inc. is known for its ability to help emerging growth companies build a following among retail and institutional investors.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
For info on presenting as a public company, speaker or media sponsor contact
Cali Van Zant: 800-665-0411 - cvanzant@investorideas.com
Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
Source - Investorideas.com, SmallCapVoice.com

Corporate Update for Argentina Gold Stock, Soltera Mining Corp. (OTCPK: SLTA)

April 4, 2011 (Investorideas.com mining stocks newswire) - www.InvestorIdeas.com, a leader in investor research in multiple sectors including gold and mining stocks publishes the following corporate update issued by Soltera Mining Corp. (OTCPK:SLTA, FRANKFURT: SN7).

Soltera Mining Corp. (OTCPK:SLTA, FRANKFURT: SN7). CORPORATE UPDATE
Soltera Mining Corp. (SLTA) has filed an 8K with the SEC regarding further funds coming to the Company from Goldlake Italia S.p.A.
Read the filing in full here: http://1.usa.gov/egfwSN
Summary of 8K:
On March 15, 2011, the Board of Directors authorized the issuance of 999,550 restricted units at a subscription price of $0.10 per restricted unit pursuant to the terms and conditions of the Financing Agreement with Goldlake Italia S.p.A. Each restricted unit consisted of one restricted shares of common stock in the capital of Soltera and one non-transferable share purchase warrants. Each restricted whole warrant enabled the holder to purchase two additional restricted shares of common stock in the capital of Soltera at a price of $0.15 per restricted share for a period of two years exercisable from September 15, 2011 to March 14, 2013.
Goldlake still have the option of exercising the balance of US$900,000 under the terms of the Financing Agreement signed on June 9, 2010.
Concerning the sampling program of late last year, the surface rock chip and channel samples were initially prepared in the field and then sent to an internationally recognized Australian/Canadian laboratory in December with operative office also in Argentina. At the laboratory, they were divided into groups and split into different sieve size fractions, with some fractions being crushed and ground. All the fractions will be analyzed with a view to optimizing processing plant configuration. Some analyses are being carried out at a laboratory in Peru and some at a specialized laboratory in Canada. This whole process has to be done with care and takes longer than standard gold assays.
Fabio Montanari
President & CEO
Soltera Mining Corp.
phone: 1-888-768-5552
info@solteramining.com
www.solteramining.com
Safe Harbor Statement: Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Information or opinions in this document are presented solely for informative purposes and are not intended nor should be construed as investment advice. We encourage you to carefully review the Company with your investment advisor and verify any information that is important to your investment decision.
Investors can view the mining company profile for Soltera Mining Corp. at http://www.investorideas.com/CO/SLTA/
Soltera Mining Corp. (OTCPK: SLTA) is a gold exploration company concentrating on its large-scale El Torno Gold Project in the Province of Jujuy in north-west Argentina. Soltera is an unusual exploration company in the sense that it is following two distinct lines of action: the first is to explore potentially large vein and dispersed gold deposits that occur within the 78 km2 title area; while the second is to develop the easily exploited and substantial surficial gold deposits that have formed by weathering of the underlying gold-bearing bed rocks.
Visit the company website at http://www.solteramining.com/
Properties Page:http://www.solteramining.com/index.php?option=com_content&task=view&id=19&Itemid=74
Request news and stock alerts from Soltera Mining Corp. http://www.investorideas.com/Resources/Newsletter.asp
About our Mining Portals:
www.Gold-MiningStocks.com and www.MiningSectorStocks.com are research portals within the InvestorIdeas.com content umbrella, featuring industry and stock news, exclusive articles and financial columnists, audio interviews and podcasts, investor conferences, blogs, and a directory of over 1300 mining stocks.
Research Mining stocks with the Investor Ideas Mining stocks Directory
Preview here:http://www.investorideas.com/Gold_Stocks/Stocks_List.asp
Disclaimer: The following company profile release for Soltera Mining is a paid for submission as a showcase companies (five hundred per month) Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions, company profile submissions and online advertising.
Disclaimer/Disclosure: http://www.investorideas.com/About/Disclaimer.asp
http://www.investorideas.com/About/News/Clientspecifics.asp
For Additional Information about Investorideas.com mining portals and becoming a showcase stock:
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Disclosure: SLTA is a paid advertising client on Investorideas.com and our mining portals.

Visit the SLTA showcase profile at Investorideas.com
Request News and Info on SLTA

Enhanced Oil Recovery Technologies and Higher Energy Prices Enable Economical Production from U.S. Shale Reserves

Point Roberts WA - April 1, 2011� www.Investorideas.com, an investor research portal specialized in sector research including energy stocks, publishes new CFA commentary from Patrick J. Murphy on US Shale Plays, featuring junior oil and gas stock, American Petro-Hunter, Inc. (OTC.BB: AAPH).
Patrick J. Murphy is the owner of Murphy Analytics LLC, a provider of sponsored research coverage on smallcap stocks.
"With horizontal drilling, today's oil and gas industry has an extraordinary capability: the power to navigate three dimensionally through the earth, contacting and economically producing resources while minimizing surface disruption."
This commentary from a DOE report, "Environmental Benefits of Advanced Oil and Gas Exploration and Production Technology”, captures the enormous opportunity made possible by the technological advances pushed forward by Halliburton (NYSE: HAL) and others driven to find an economical approach to tapping into what the U.S. Geological Survey estimates is 2.5 to 3 trillion barrels of proven resources of shale oil throughout the world. Importantly for domestic producers, studies estimate that the U.S. has as much as 73% of the world's recoverable shale oil in contrast to only 5% of the world's recoverable crude oil.
Historically, vertically drilled wells were the most economical method for tapping into the formations that have produced abundant quantities of the world's oil and gas. However, as producers began to comprehend the magnitude of the opportunity in the Barnett Shale, the Woodford Shale and elsewhere, it became clear that exploiting unconventional resources would require unconventional technology.
As explained by the Energy Information Administration of the DOE, because oil and gas reserves are much wider than they are deep, which is particularly true of U.S. shale reserves, horizontal drilling achieves the technical objective of intersecting a reserve in a manner that maximizes contact with the reserve. Developing this expertise took time, however, and this technical evolution is highlighted in a Halliburton white paper that points out the lag between the identification and commercialization of the Barnett Shale opportunity:
"Lacking an efficient means of production, U.S. shale gas reserves were largely ignored so long as market conditions made reserves more costly to produce than conventional sources. In fact, one of the first recognized major shale gas plays, the Barnett Shale of Texas, was under investigation as early as 1981, but not until 1995 was the hydraulic fracturing technology available that successfully brought in the gas at commercial rates. Then, five of the initial six wells each began producing more than two million cubic feet of gas per day and, soon after, introduction of horizontal drilling began to extend the basin where today two percent of all the gas consumed daily in the U.S. is produced.”
The delay in utilizing horizontal drilling and hydraulic fracturing was not solely the result of the lack of technical knowledge, but also a function of the higher relative cost of these technologies, which did not prove to be economical when oil and gas prices were low. Although the cost of drilling a horizontal well can be as much as two to three times higher than the cost of drilling a vertical well, this higher cost must be measured against a higher production factor, which can be 15 - 20 times higher for a horizontal well. However, given that some degree of uncertainty is inherent in all drilling, and in light of the volatility of fossil fuel prices, incurring a drilling expense that is known to be higher is easier to tolerate when oil is bouncing around at $100 per barrel rather than $30 per barrel. The influence of higher fossil fuel prices is highlighted in the previously referenced Halliburton white paper on U.S. shale gas:

"Current increasing demand and lagging supply mean high prices for both oil and gas, making exploitation of North American unconventional gas plays suddenly far more lucrative for producers. One of the most important such plays to emerge has been U.S. shale gas.”
Although drilling techniques must adapt to the unique geological characteristics of each play, success in understanding the Woodford shale opportunity is evidenced by the dramatic increase in the number wells drilled there - American Petro-Hunter (OTCBB: AAPH) CEO Robert McIntosh estimates that there were 1,300 vertical and wells drilled in the Woodford from 2003 - 2010, with Devon Energy (NYSE: Devon) being particularly active.
Citing the success of other exploration and production company's around American Petro-Hunter's properties in Payne County, Oklahoma, CEO McIntosh recently noted that the Company's plans for the balance of 2011 call primarily for the development of horizontal wells. Although AAPH recently commenced operations on a vertical well due to the location's unique characteristics, the Company has noted that horizontal wells in the region have produced upwards of 500 barrels per day, some 2 - 3 times the potential estimated for the vertical well, which is scheduled to be the last vertical test planned by AAPH.
The evolution of horizontal drilling and hydraulic fracturing technology, coupled with higher energy prices has created a domestic exploration and production opportunity that is large enough to meet U.S. energy demand for decades to come. With the success exploitation of the Barnett Shale, attention is moving towards similar opportunity in the Woodford Shale and elsewhere. For those interested in investing in U.S. domestic oil and gas and in the opportunity created by technical evolution and rising energy prices, industry giants like Halliburton and Devon Energy may be of interest, and there also may be opportunity in junior exploration and production companies like American Petro-Hunter, which is working to realize the potential in the Woodford Shale and elsewhere in the U.S.
Patrick Murphy Bio:
Patrick J. Murphy is the owner of Murphy Analytics LLC, a provider of sponsored research coverage on smallcap stocks. Mr. Murphy has over 15 years of capital markets experience providing institutional investment and transaction analysis across a range of asset classes including microcap equities, commercial real estate debt and equity, municipal derivatives and public finance, venture capital, fixed income, CMBS and mortgage REIT's. In addition to his work with Murphy Analytics, Mr. Murphy also serves as a consultant to a municipal derivatives advisory firm. Mr. Murphy is an alumnus of the University of Notre Dame (1991), with an undergraduate degree in Economics, and earned a Masters Degree in Finance from St. Louis University in 1997. Mr. Murphy is a CFA Charterholder and a member of the CFA Society of St. Louis.
Patrick Murphy Disclaimer:
Readers are advised that the above article is solely for information purposes and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. The views expressed herein are based upon the author's analysis of the issuer's public disclosures, and assumes both their accuracy and completeness. The opinions and statements included herein are based on sources (including the companies discussed and public sources) believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy, completeness or correctness. The author has not independently verified the information contained herein. This information is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. You should review a complete information package on all companies, which should include, but not be limited to, the Company's annual report, quarterly reports, press releases and all regulatory filings. The foregoing discussion contains statements which are based on current expectations, estimates and projections, and differences from such expectations, estimates and projections can be expected.
The author, Patrick Murphy, was compensated $350 for writing this article by InvestorIdeas.com. Mr. Murphy does not own shares of any of the companies mentioned in this article. Mr. Murphy expects his research firm, Murphy Analytics, to be engaged for the provision of a research report on AAPH in March 2011.
http://www.horizontaldrilling.org/
More info: American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the hunt for domestic petroleum assets. www.americanpetrohunter.com
Company Research
http://www.aaphreport.com/
Visit the AAPH showcase profile at Investorideas.com
http://www.investorideas.com/CO/AAPH/
Request News and Info on AAPH
http://www.investorideas.com/Resources/Newsletter.asp
Contact American Petro-Hunter:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including energy and mining stocks.
Disclaimer/ Disclosure: The following news is paid for and /or published as information only for our readers. American Petro-hunter Inc. (AAPH.OB) is a showcase energy stock on Investorideas.com and all related energy portals and blogs ( averaging two thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal .This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
For Additional Information about Investorideas.com energy portals: 800-665-0411 or cvanzant@investorideas.com

Emerging Opportunities in Biodefense Part II; An interview with Aethlon Medical (OTCBB: AEMD) CEO, Jim Joyce

Point Roberts, WA - April 1, 2011 � Investorideas.com, a leader in sector research including biotech and biodefense stocks, presents the second in a series of biodefense interviews with Jim Joyce, CEO of Aethlon Medical (OTCBB: AEMD).
Read the first Q&A Interview:
http://www.investorideas.com/CO/AEMD/news/2011/03251.asp
Interview Follow-Up March 31, 2011:
InvestorIdeas: In our interview last week, we discussed the unprecedented opportunity for organizations with treatment candidates against bioterror or pandemic threats to attract non-dilutive funding support from a variety of government agencies. Are these programs really a good use for taxpayer dollars?

Mr. Joyce: Well, with the exception of treatments stockpiled against a few defined threats, our civilian and military populations remain naked against pathogen threats most likely to be weaponized in a bioterror attack or emerge naturally to trigger a pandemic outbreak. However, the fear of the next biological weapon attack or pandemic outbreak is not the only rationale for spending taxpayer dollars on these programs. It should be recognized that these programs provide the impetus for therapeutic innovation that could lead to landmark advances in healthcare.
InvestorIdeas : What kind of therapeutic innovation are we talking about?
Mr. Joyce: Since the focus of government programs has been redirected to supporting broad-spectrum countermeasures, the resulting innovation might be the introduction of life-saving therapies that are effective against pathogens created by man to circumvent traditional drugs and vaccines. Or perhaps, pathogens that might emerge naturally and therefore would not have a corresponding drug or vaccine. Much like the SARS outbreak of 2003. It would seem that such innovation would transcend the treatment of bioterror and pandemic threats to provide new therapeutic strategies against mainstream disease conditions as well.
InvestorIdeas: Do you consider Aethlon Medical to be an innovative company?
Mr. Joyce: Absolutely. Innovation by definition requires taking an entirely different and sometimes more difficult path to achieve an objective. No long ago, it was believed that only drugs or vaccines could address viral infections. We didn't agree. So we created a medical device, the Hemopurifier® that might just redefine the premise of how to treat infectious disease. In fact, we are gathering evidence that suggests our Hemopurifier® has attributes beyond the capabilities of drug agents.
InvestorIdeas: Can you elaborate further on that statement?
Mr. Joyce: First and foremost, I am not aware of any drug candidate that has demonstrated our breadth of capabilities against viral pathogens, and certainly, a vaccine strategy cannot addresses multiple strains, species, and families of viral pathogens. Beyond that, our device fills an unmet medical need of removing immunosuppressive proteins shed by viruses, and we recently discovered our Hemopurifier® captures disease enhancing exosomes that underlie both infectious disease and cancer. Yet, while these attributes may be beyond the reach of traditional drug and vaccine strategies, they offer to improve the benefit of drug and vaccine strategies. In that regard, I would like to think the combination of our device with drugs would provide for a win-win scenario.
InvestorIdeas: In closing, is there anything else you would like to tell us about your Hemopurifier®?
Mr. Joyce: The device has demonstrated great promise in treating HIV and Hepatitis-C patients and it should be considered the leading broad-spectrum treatment countermeasure against biological weapons and naturally emerging pandemic threats. We are now seeking to leverage the technology platform utilized to create our Hemopurifier®, to build new therapeutic candidates to address other disease conditions, including a device targeted to reduce the occurrence of sepsis.
About Aethlon Medical ( OTCBB: AEMD )
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
1. Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2. Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3. Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4. Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC (OTC BB: AEMD) Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock) Effective March 15, 2011      
800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011

Electric Car Stocks Trading Alert; EVCARCO, Inc. (OTCBB: EVCA) to Participate in the Grand Opening of Dezer Collection Museum

FT. WORTH, TX � March 31, 2011 (Investorideas.com renewable energy/green newswire) - EVCARCO, Inc. (OTCBB:EVCA) announced today that its Executive Team will attend and represent the EVCARCO's Future Driven� brand in the Grand Opening of the Dezer Collection Museum and Pavilion in North Miami, Florida on April 1st. The museum is located at 2000 NE 146th Street in the North Miami. The Gala will host the elite of Southern Florida and will present EVCARCO to a highly important base of new clients and automotive aficionados.

The facility has on display over 600 vintage and exotic vehicles in a 250,000 square foot building that includes a food court for hosting gatherings. For more information on the museum, please visit www.dezercollection.com.
Mack Sanders, CEO of EVCARCO, stated, "EVCARCO has the privilege of working with a legend like Mr. Dezer. His interest in the automotive sector coupled with his business skills has made him a great mentor to EVCARCO; working with him, we feel that a launch of our brand on grand scale is imminent."
For more information on EVCARCO, Inc., please view: www.evcarco.com. Shareholder inquiries should be directed to (972) 571-1624.
EVCARCO, Inc. is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles. EVCARCO -- Future Driven®
This Press Release contains certain forward-looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Contact:
Investor Relations Contact:
Jack Eversull
The Eversull Group, Inc.
972-571-1624
214-469-2361 fax

Visit the EVCA showcase profile at Investorideas.com
Request News and Info on EVCA
Disclosure, Disclaimer/ EVCA is a paid advertising client on Investorideas.com and our renewable energy portals (500,000 144 shares).

Electric Car Stock Trading Alert; Tesla Motors, Inc. (NasdaqGS: TSLA) up 16% in Morning Trading

March 31, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com a leader in cleantech investor research, reports on electric car stocks and battery stocks news and trading. Tesla Motors, Inc.(NasdaqGS: TSLA) began an uptrend Thursday following Morgan Stanley upgrading it overweight from equal weight. The stock is trading at $27.65, up $3.94 (16.62%) 10:43AM EDT in morning trading.
Other headlines for the stock; Carmaker Tesla Sues BBC's 'Top Gear' Over Electric Auto Testat Bloomberg (Wed, Mar 30)
Electric Vehicle Stocks:
Company Snapshot

Tesla's goal is to produce a full range of electric cars, from premium sports cars to mass-market vehicles - relentlessly driving down the cost of electric vehicles. It is currently the only automaker in the United States that builds and sells highway-capable EVs in serial production. Palo Alto, California-based Tesla designs and manufactures EVs and EV powertrain components. Tesla has delivered more than 1,500 Roadsters to customers in North America, Europe and the Asia Pacific Region. The Tesla Roadster accelerates faster than most sports cars yet produces no emissions.
Company Snapshot
EVCARCO (OTC.BB:EVCA) - Green , Electric Cars and Natural Gas Vehicles
EVCARCO (OTC.BB:EVCA) (www.evcarco.com) is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles.
Visit the Company showcase at Investorideas.com:
Research electric car stocks and green auto stocks, lithium stocks - with the renewable energy stocks directory Research over 1300 green stocks - Investors also have the option to access the directory as part of the Investor Ideas Investors also have the option to access the directory as part of the Investor Ideas Membership premium content that currently features an additional 10 stock directories, including the water stocks directory and all cleantech stock directories. http://www.investorideas.com/membership/
Investors - sign up for free stock alerts and investor news alerts
http://www.investorideas.com/Resources/Newsletter.asp
About Our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. Disclosure: Investorideas is compensated by featured green companies EVCARCO (OTCBB: EVCA) is a showcase stock at Investorideas.com and compensated the site 500,000 144 shares in lieu of cash compensation.
To become a showcase company, contact us below.
For more information contact:
Email: dvanzant@investorideas.com or Cali at cvanzant@investorideas.com
Source: www.Investorideas.com

Security Stocks; TransTech Systems, a Subsidiary of Visualant (OTCBB:VSUL), to Exhibit at the International Security Conference & Exposition

SEATTLE - March 31, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., is pleased to announce that TransTech Systems will be exhibiting at the International Security Conference & Exposition from April 6-8, 2011 at the Sands Expo & Convention Center in Las Vegas, NV.

The International Security Conference & Exposition (ISC West) is one of the fastest growing tradeshows in North America according to the publication Tradeshow Week. With over 23,000 industry professionals and 14,600 security buyers, ISC West is certainly the nation's largest security event of the year. ISC West will be hosting education sessions from April 5-7, 2011 as well as the exposition from April 6-8, 2011. See www.iscwest.com for more information.
TransTech Systems (www.ttsys.com) will be exhibiting the latest in identification card printing and encoding systems and building access control products from manufacturers such as Evolis, NiSCA, FarPointe, and Datacard. TransTech also will be demonstrating the new Visualant Spectral Pattern Matching technology. See these and other popular security industry products on display in TransTech's booth #22129.
We will post this press release on the Visualant website at www.visualant.net. If we have an email address for you, we will send you a copy of our press releases electronically. We want to remind you that if you have not already done so, please enter your email and other information on the form on the website at: http://visualant.net/contactus.html.
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com

Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)

Wind Stock Trading Alert; Clean Wind Energy Tower, Inc. (OTCBB: CWET) Trading up 13.64%

Point Roberts, WA - March 30, 2011 - Investorideas.com, a leader in cleantech stock research, releases a trading alert for wind stock, Clean Wind Energy Tower, Inc (OTCBB: CWET). The stock is trading at $0.25, up $ 0.03 (13.64%) in morning trading.
The Company recently announced it filed with the United States Patent & Trademark Office "A Petition to Make Special under Accelerated Examination Program," a patent application titled Efficient Energy Conversion Devices & Methods. The application covers specific aspects of deploying multiple turbines in a wind tunnel coupled to a novel hydraulic system capable of maintaining high efficiency hydraulic to electric conversion under a wide variance of wind speeds. The ultimate goal is to maximize the capture and utilization of all available wind energy in any given wind tunnel, as well as providing a consistency of power output during deviations in wind speed.
News:http://www.investorideas.com/CO/CWE/news/2011/03071.asp
Clean Wind Energy Tower, Inc (OTCBB:CWET) www.cleanwindenergytower.com
Clean Wind Energy, Inc. a wholly owned subsidiary of Clean Wind Energy Tower, Inc, is designing and preparing to develop, and construct large “Downdraft Towers” that use benevolent, non-toxic natural elements to generate electricity and clean water economically by integrating and synthesizing numerous proven as well as emerging technologies. In addition to constructing Downdraft Towers in the United States and abroad, the Company intends to establish partnerships at home and abroad to propagate these systems and meet increasing global demand for clean water and electricity.

p>Clean Wind has assembled a team of experienced business professionals, engineers and scientists with access to the breakthrough energy research upon which this technology is founded and the proven ability to bring the idea to market. Clean Wind has filed several patents that the Company believes will further enhance this potentially revolutionary technology. Visit the showcase page at Investorideas.com: http://www.investorideas.com/CO/CWE/
Contact the company:
410-972-4713
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor alerts including news on Clean Wind Energy,
http://www.investorideas.com/Resources/Newsletter.asp
Research more wind stocks with the renewable energy stocks directory
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one thousand five hundred per month, 100,000 shares 144) to be showcased as a renewable energy stock within its hub of sites and blogs.Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. This site is currently compensated by featured companies, news submissions and online advertising. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp , http://www.investorideas.com/About/News/Clientspecifics.asp
For more information about Investorideas.com green stocks contact:
800.665.0411, Email: dvanzant@investorideas.com or cvanzant@investorideas.com

Biotech/Pharma Stock News; BioSante Pharmaceuticals (NASDAQ: BPAX) Completes Enrollment in Both Pivotal LibiGel® Phase III Efficacy Trials

LINCOLNSHIRE, Ill. - March 30, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that enrollment of subjects in the second of two pivotal Phase III LibiGel (testosterone gel) safety and efficacy trials has been completed. Enrollment in the first LibiGel efficacy trial was completed in February. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.

"This is an important achievement for BioSante and a key step toward completing the LibiGel Phase III clinical development program," said Joanne Zborowski, BioSante's vice president of clinical development. "There are more than 1,000 subjects in the efficacy trials and we anticipate announcing top-line efficacy data this fall. In addition, we have over 3,000 subjects enrolled in our LibiGel Phase III safety study," she added.
Phillip B. Donenberg, BioSante's senior vice president of finance & CFO commented, "This key LibiGel achievement, coupled with our successful financing strategy, guarantees a solid timeline for Phase III efficacy data, with sufficient funds to finance our operations and LibiGel clinical development through that data and well into 2012. As a result, we have removed near-term financial risk from BioSante without the need for additional funds."
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). Enrollment has been completed in the two on-going Phase III efficacy trials which are double-blind, placebo-controlled trials of approximately 500 surgically menopausal women each. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
BioSante also is conducting a Phase III LibiGel safety study, a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that has enrolled over 3,000 women. The study will continue for a total of five years, however, BioSante can use the safety study data as part of an NDA submission after an average of 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).

Woodford Shale Emerging as a Leading Domestic Oil and Gas Play

Point Roberts WA - March 30, 2011 - www.Investorideas.com, an investor research portal specialized in sector research including oil and gas stocks, releases the following CFA commentary on the Woodford Shale play from Patrick J. Murphy, featuring American Petro-Hunter, Inc. (OTC.BB:AAPH).

Patrick J. Murphy is the owner of Murphy Analytics LLC, a provider of sponsored research coverage on smallcap stocks.
Woodford Shale Emerging as a Leading Domestic Oil and Gas Play
As noted by American Petro-Hunter (OTCBB:AAPH) CEO Robert McIntosh in the Company's January 2011 Corporate Newsletter, production in the Woodford Shale has skyrocketed over the last few years. CEO McIntosh and others have referred to the Woodford as a world class oil and gas target, an assertion that seems justified given that the Woodford Shale now ranks second domestically in gas production and fifth in oil production. Following is data and commentary related to the operations and outlook for some of the Woodford Shale's most active players.
Devon Energy (NYSE: DVN): In a presentation at the Oppenheimer Unconventional Oil and Gas Conference, DVN noted that its Woodford assets benefit from a low cost of entry at approximately $2,200 per acre and a low average royalty burden at approximately 21%. The Company also notes that it recently completed construction of a gas processing plant, and after drilling 87 wells in 2010, DVN plans to drill over 200 wells in the Cana-Woodford Shale in 2011. Discussing the Company's Q4 2010 earnings, CFO and Executive Vice President Jeffrey Agosta commented on DVN's interest in the shale:
"Moving to the Cana-Woodford Shale in Western Oklahoma, we continue to add to our acreage position during the fourth quarter and now have approximately 243,000 net acres. Devon is currently operating 23 out of the 39 rigs running play-wide."
Marathon Oil (NYSE: MRO): At a recent Credit Suisse conference, MRO noted its interest in the Anadarko Woodford Shale play, with 3 rigs operating currently and 8 planned by the end of 2011. The company also observed that returns there are among the highest of domestic resource plays, and while exiting 2010 at approximately 1,500 BOED, MRO estimates that, by 2015, it could reach a peak rate of 30,000 BOED. In the Company's Q4 2010 conference call, Executive Vice President David Roberts noted that MRO plans to more than double its acreage in the area:
"Marathon also holds 86,000 acres in the Anadarko Woodford area, an area where we have operated for decades, and we have line in sight on new opportunity to increase that position to over 100,000 acres shortly. Importantly, we will have eight rigs in the play by 2011 by the end of this year."
Continental Resources (NYSE: CLR): In its October 2010 Investor Day Presentation, CLR noted that the Company is the top leaseholder in Anadarko Woodford, with 252,000 net lease acres. The Company also notes that its first Woodford well was completed in Q1 08, and had increased to over 25 by July of 2010. For 2011, 20% of CLR's $1.4 billion capex budget will be spent in Woodford, which it refers to as one of the plays critical for tripling the Company's production from 2010 to 2014. Commenting on CLR's view of the Woodford during the Q4 earnings call, President and COO Jeffrey Hume said:
"We're very encouraged with what we are seeing in Anadarko Woodford. In early 2010, we stepped out into the Northwest in the Anadarko Woodford in Blaine and Dewey Counties and demonstrated that the Anadarko Woodford was much larger and had more potential than just the core Canadian County part of the play. We were successful and other operators have followed. Activity has ramped up dramatically in the Northwest Cana where there are now 43 rigs drilling."
Cimarex Energy (NYSE: XEC): Noted in the Credit Suisse presentation, XEC has over 100,000 net acres leased in the western Oklahoma Cana-Woodford play, and with eight operating rigs, this is the Company's largest single investment area. In 2010, XEC spent $335 million in capex in Woodford, increasing by 65% over 2009 its net wells drilled in the region, and XEC notes it expects "significant future drilling" in the Woodford. Commenting on the Company's view of the Woodford opportunity in the Q4 earnings call, Executive Vice President of Exploration Thomas Jorden stated:
"There's a lot here we're still trying to figure out, but we are absolutely delighted with this play and what it will contribute to our 2011 and beyond. This is a huge, huge impact to our reserves production and future capital program. We're having very, very good results."
Newfield Exploration (NYSE: NFX): As noted in its presentation for the Simmons & Company International Energy Conference, NFX plans to double or triple the number of wells drilled 2011 in the Woodford Shale, where the Company has 172,000 net acres. NFX also plans to continue to assess additional locations in the western area of its acreage, which the Company considers to be "oily drilling" and in the eastern area of its acreage, which NFX characterizes as more gas prone. In the Company's Q4 2010 earnings call, Chairman, CEO and President Lee Boothby address the Company's growing understanding of the Woodford play as well as the commitment to further investment there:
"Last week, we talked about a new play for us in the area: the Oily Woodford. Over the last two years, we've drilled a half a dozen wells to assess the Woodford on the western side of our Arkoma Basin acreage. We see the potential to drill more than 100 wells in this new play area, a great option to have during a period of low gas prices. For those of you that remember our original Woodford maps or toured the Woodford Shale back in 2006, you may recall a line that ran north to south across our acreage, separating the basin centered gas acreage to the east from the wet gas oil prone acreage to the west. Our tremendous learning curve in drilling efficiency gains and learnings relative to oil shales for the last couple of years have helped us crack the code in this new play area…Because of the oil and rich gas, the economics of this play have pushed it toward the top of our investment list. We plan to drill 12 to 18 wells here in 2011."
New production technology and higher overall energy prices have not only made shale gas reserves an important of our domestic energy policy, but also create an appealing investment opportunity for those interested in the major oil and gas producers as well as the juniors, like American Petro-Hunter. While the majors ramp up production much more quickly than is possible for the juniors, the smaller producers do benefit significantly from the knowledge gained by the majors, and are able to incorporate this information into their drilling activity, enabling juniors like AAPH and others to benefit from the significantly larger capex budgets of the majors, and making them an investment opportunity worth investigating.
Patrick Murphy Bio:
Patrick J. Murphy is the owner of Murphy Analytics LLC, a provider of sponsored research coverage on smallcap stocks. Mr. Murphy has over 15 years of capital markets experience providing institutional investment and transaction analysis across a range of asset classes including microcap equities, commercial real estate debt and equity, municipal derivatives and public finance, venture capital, fixed income, CMBS and mortgage REIT's. In addition to his work with Murphy Analytics, Mr. Murphy also serves as a consultant to a municipal derivatives advisory firm. Mr. Murphy is an alumnus of the University of Notre Dame (1991), with an undergraduate degree in Economics, and earned a Masters Degree in Finance from St. Louis University in 1997. Mr. Murphy is a CFA Charterholder and a member of the CFA Society of St. Louis.
Patrick Murphy Disclaimer:
Readers are advised that the above article is solely for information purposes and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. The views expressed herein are based upon the author's analysis of the issuer's public disclosures, and assumes both their accuracy and completeness. The opinions and statements included herein are based on sources (including the companies discussed and public sources) believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy, completeness or correctness. The author has not independently verified the information contained herein. This information is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. You should review a complete information package on all companies, which should include, but not be limited to, the Company's annual report, quarterly reports, press releases and all regulatory filings. The foregoing discussion contains statements which are based on current expectations, estimates and projections, and differences from such expectations, estimates and projections can be expected.
The author, Patrick Murphy, was compensated $350 for writing this article by InvestorIdeas.com. Mr. Murphy does not own shares of any of the companies mentioned in this article. Mr. Murphy expects his research firm, Murphy Analytics, to be engaged for the provision of a research report on AAPH in March 2011.
More info: American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the hunt for domestic petroleum assets. www.americanpetrohunter.com
Company Research
http://www.aaphreport.com/
Visit the AAPH showcase profile at Investorideas.com
http://www.investorideas.com/CO/AAPH/
Request News and Info on AAPH
http://www.investorideas.com/Resources/Newsletter.asp
Contact American Petro-Hunter:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including energy and mining stocks.
Disclaimer/ Disclosure: The following news is paid for and /or published as information only for our readers. American Petro-hunter Inc. (AAPH.OB) is a showcase energy stock on Investorideas.com and all related energy portals and blogs ( averaging two thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal .This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
For Additional Information about Investorideas.com energy portals: 800-665-0411 or cvanzant@investorideas.com

Visit the AAPH showcase profile at Investorideas.com
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) Oct 2010 - one month showcase energy stock on Investorideas.com and energy portals and blogs (three thousand per month)